Oculopharyngeal muscular dystrophy: A polyalanine myopathy

Current Neurology and Neuroscience Reports

Volumn 9, Issue 1, 2009, Pages 76-82

  Brais, Bernard ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PEPTIDE; POLYADENYLIC ACID BINDING PROTEIN; POLYALANINE; UNCLASSIFIED DRUG;

DIFFERENTIAL DIAGNOSIS; GENETIC COUNSELING; GENETICS; HUMAN; METABOLISM; MOLECULAR BIOLOGY; MUTATION; OCULOPHARYNGEAL MUSCULAR DYSTROPHY; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW;

DIAGNOSIS, DIFFERENTIAL; GENETIC COUNSELING; HUMANS; MOLECULAR BIOLOGY; MUSCULAR DYSTROPHY, OCULOPHARYNGEAL; MUTATION; PEPTIDES; POLY(A)-BINDING PROTEIN I;

EID: 59149101614     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-009-0012-y     Document Type: Article

References (49)

1. Victor M, Hayes R, Adams RD: Oculopharyngeal muscular dystrophy: a familial disease of late life characterized by dysphagia and progressive ptosis of the eyelids. N Engl J Med 1962, 267:1267-1272.
2. Tomé FM, Fardeau M: Nuclear inclusions in oculopharyngeal muscular dystrophy. Acta Neuropathol 1980, 49:85-87. (Pubitemid 10139969)
3. Brais B, Bouchard JP, Xie YG, et al.: Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat Genet 1998, 18:164-167. (Pubitemid 28082465)
4. Brais B, Xie YG, Sanson M, et al.: The oculopharyngeal muscular dystrophy locus maps to the region of the cardiac alpha and beta myosin heavy chain genes on chromosome 14q11.2-q13. Hum Mol Genet 1995, 4:429-434.
5. Bouchard JP, Brais B, Brunet D, et al.: Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul Disord 1997, 7(Suppl 1):S22-S29.
6. Becher MW, Morrison L, Davis LE, et al.: Oculopharyngeal muscular dystrophy in Hispanic New Mexicans. JAMA 2001, 286:2437-2440. (Pubitemid 33098162)
7. Duranceau A, Forand MD, Fauteux JP: Surgery in oculopharyngeal muscular dystrophy. Am J Surg 1980, 139:33-39. (Pubitemid 10207542)
8. Tomé FM, Chateau D, Helbling-Leclerc A, et al.: Morphological changes in muscle fibers in oculopharyngeal muscular dystrophy. Neuromuscul Disord 1997, 7(Suppl 1):S63-S69.
9. Blumen SC, Brais B, Korczyn AD, et al.: Homozygotes for oculopharyngeal muscular dystrophy have a severe form of the disease. Ann Neurol 1999, 46:115-118. (Pubitemid 29314390)
10. Calado A, Carmo-Fonseca M: Localization of poly (A)-binding protein 2(PABP2) in nuclear speckles is independent of import into the nucleus and requires binding to poly (A) RNA. J Cell Sci 2000, 113 (Pt 12):2309-2318. (Pubitemid 30426844)
11. Uyama E, Tsukahara T, Goto K, et al.: Nuclear accumulation of expanded PABP2 gene product in oculopharyngeal muscular dystrophy. Muscle Nerve 2000, 23:1549-1554.
12. Becher MW, Kotzuk JA, Davis LE, et al.: Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly (A) binding protein 2. Ann Neurol 2000, 48:812-815.
13. Abu-Baker A, Messaed C, Laganiere J, et al.: Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum Mol Genet 2003, 12:2609-2623. (Pubitemid 37304684)
14. Bao YP, Cook LJ, O'Donovan D, et al.: Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J Biol Chem 2002, 277:12263-12269. (Pubitemid 34952794)
15. Calado A, Tomé FM, Brais B, et al.: Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly (A) binding protein 2 aggregates which sequester poly (A) RNA. Hum Mol Genet 2000, 9:2321-2328.
16. Kim YJ, Noguchi S, Hayashi YK, et al.: The product of an oculopharyngeal muscular dystrophy gene, poly (A) - binding protein 2, interacts with SKIP and stimulates muscle-specific gene expression. Hum Mol Genet 2001, 10:1129-1139. (Pubitemid 32487536)
17. Corbeil-Girard LP, Klein AF, Sasseville AM, et al.: PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol Dis 2005, 18:551-567. (Pubitemid 40332714)
18. Robinson DO, Wills AJ, Hammans SR, et al.: Oculopharyngeal muscular dystrophy: a point mutation which mimics the effect of the PABPN1 gene triplet repeat expansion mutation. J Med Genet 2006, 43:267-271.
19. Nakamoto M, Nakano S, Kawashima S, et al.: Unequal crossing-over in unique PABP2 mutations in Japanese patients: a possible cause of oculopharyngeal muscular dystrophy. Arch Neurol 2002, 59:474-477. (Pubitemid 34208160)
20. Gurtler N, Plasilova M, Podvinec M, et al.: A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy. Laryngoscope 2006, 116:111-114. (Pubitemid 44383973)
21. Tremolizzo L, Galbussera A, Tagliabue E, et al.: An apparently sporadic case of oculopharyngeal muscular dystrophy: the first Italian report. Neurol Sci 2007, 28:339-341.
22. Hebbar S, Webberley MJ, Lunt P, et al.: Siblings with recessive oculopharyngeal muscular dystrophy. Neuromuscul Disord 2007, 17:254-257. (Pubitemid 46413754)
23. Semmler A, Kress W, Vielhaber S, et al.: Variability of the recessive oculopharyngeal muscular dystrophy phenotype. Muscle Nerve 2007, 35:681-684. (Pubitemid 46676860)
24. Messaed C, Dion PA, Abu-Baker A: et al.: Soluble expanded PABPN1 promotes cell death in oculopharyngeal muscular dystrophy. Neurobiol Dis 2007, 26:546-557. This paper is the first to clearly put forward experimental data to suggest that soluble PABPN1 is likely the form responsible for toxicity in OPMD, while the aggregate forms may be protective. (Pubitemid 46778990)
25. Kuhn U, Wahle E: Structure and function of poly (A) binding proteins. Biochim Biophys Acta 2004, 1678:67-84. (Pubitemid 38626168)
26. Bear DG, Fomproix N, Soop T, et al.: Nuclear poly (A) - binding protein PABPN1 is associated with RNA polymerase II during transcription and accompanies the released transcript to the nuclear pore. Exp Cell Res 2003, 286:332-344. (Pubitemid 36566445)
27. Calado A, Kutay U, Kuhn U, et al.: Deciphering the cellular pathway for transport of poly (A)-binding protein II. RNA 2000, 6:245-256. (Pubitemid 30091595)
28. Lodderstedt G, Hess S, Hause G, et al.: Effect of oculopharyngeal muscular dystrophy-associated extension of seven alanines on the fibrillation properties of the N-terminal domain of PABPN1. FEBS J 2007, 274:346-355. This paper shows clearly that fibril formation of expanded N-terminal PABPN1 is faster in a concentration-dependent manner than wild-type when placed in the presence of low amounts of fragmented seeds of aggregated protein. Furthermore, fibril morphology was different between the two types of fragments in a way that increased the resistance of the mutated form to a strong solubilization agent. This work is the first to clearly show at the structural level that the polyalanine expansion induces conformational changes that significantly modify the protein's biochemical characteristics. (Pubitemid 46046645)
29. Lodderstedt G, Sachs R, Faust J, et al.: Hofmeister salts and potential therapeutic compounds accelerate in vitro fibril formation of the N-terminal domain of PABPN1 containing a disease-causing alanine extension. Biochemistry 2008, 47:2181-2189. This study describes the influence of various substances on a fibrillar assay of the N-terminal PABPN1 domain. Interestingly, it shows that doxycycline and trehalose, two molecules previously shown to diminish mutated PABPN1 toxicity in a mouse transgenic model, cause an increase in fibril formation. This provides indirect evidence that increased aggregation may in fact be protective or alternatively that these substances, by ensuring a better conformation of the soluble mutated forms, may slow the disease process. (Pubitemid 351287144)
30. Rohrberg J, Sachs R, Lodderstedt G, et al.: Monitoring fibril formation of the N-terminal domain of PABPN1 carrying an alanine repeat by tryptophan fluorescence and real-time NMR. FEBS Lett 2008, 582:1587-1592. This paper shows that interruption of the polyalanine domain by a tryptophan will modify the protein from an insoluble to soluble species, increasing the evidence that the length of noninterrupted polyalanine domain of PABPN1 influences its aggregative properties.
31. Sackewitz M, Scheidt HA, Lodderstedt G, et al.: Structural and dynamical characterization of fibrils from a disease-associated alanine expansion domain using proteolysis and solid-state NMR spectroscopy. J Am Chem Soc 2008, 130:7172-7173. This provides the first structural evidence that the proximity of glycine residues in the N-terminal part of PABPN1 plays a role in the flexibility of the fibril core key for aggregation. (Pubitemid 351813179)
32. Sackewitz M, von Einem S, Hause G, et al.: A folded and functional protein domain in an amyloid-like fibril. Protein Sci 2008, 17:1044-1054. This paper surprisingly shows that expansion from 10 to 17 alanines of the N-terminal domain of PABPN1 appears to decrease fibrillar formation, providing structural evidence that the mutated form may in fact have a greater negative impact on physiologic interaction between PABPN1 molecules with itself and other partners. (Pubitemid 351749210)
33. Davies J, Wang L, Garcia-Oroz L, et al.: Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat Med 2005, 6:672-677. (Pubitemid 40868309)
34. Davies JE, Sarkar S, Rubinsztein DC: Treha lose reduces aggregate formation and delays pathology in a transgenic mouse model of oculopharyngeal muscular dystrophy. Hum Mol Genet 2006, 15:23-31. (Pubitemid 43020101)
35. Ge H, Zhou D, Tong S, et al.:.: Crystal structure and possible dimerization of the single RRM of human PABPN1. Proteins 2008, 71:1539-1545. This paper provides evidence for the structural dimerization of the RNA recognition motif (RRM or RNA-binding domain) of PABPN1. (Pubitemid 351564072)
36. Bao YP, Sarkar S, Uyama E, et al.: Congo red, doxycycline, and HSP70 overexpression reduce aggregate formation and cell death in cell models of oculopharyngeal muscular dystrophy. J Med Genet 2004, 41:47-51. (Pubitemid 38125688)
37. Hino H, Araki K, Uyama E, et al.: Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy. Hum Mol Genet 2004, 13:181-190. (Pubitemid 38111356)
38. Ravikumar B, Duden R, Rubinsztein DC: Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy. Hum Mol Genet 2002, 11:1107-1117. (Pubitemid 34521091)
39. Catoire H, Pasco MY, Abu-Baker A, et al.:.: Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Hum Mol Genet 2008, 17:2108-2117. This paper describes the first nematode model of OPMD. It provides convincing evidence that inhibition of longevity modulators sirtuins by inhibitors such as sirtinol may favorably diminish the mutated PABPN1 toxicity, and it provides some evidence that soluble PABPN1 in the nematode appears to be the more toxic form. (Pubitemid 351911980)
40. Chartier A, Benoit B, Simonelig M: A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J 2006, 25:2253-2262.
41. Wang Q, Mosser DD, Bag J: Induction of HSP70 expression and recruitment of HSC70 and HSP70 in the nucleus reduce aggregation of a polyalanine expansion mutant of PABPN1 in HeLa cells. Hum Mol Genet 2005, 14:3673-3684. (Pubitemid 41754667)
42. Verheesen P, de Kluijver A, van Koningsbruggen S, et al.: Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum Mol Genet 2006, 15:105-111. (Pubitemid 43020109)
43. Berciano MT, Villagra NT, Ojeda JL, et al.: Oculopharyngeal muscular dystrophy-like nuclear inclusions are present in normal magnocellular neurosecretory neurons of the hypothalamus. Hum Mol Genet 2004, 13:829-838. (Pubitemid 38515212)
44. Villagra NT, Bengoechea R, Vaque JP, et al.: Nuclear compartmentalization and dynamics of the poly (A)-binding protein nuclear 1 (PABPN1) inclusions in supraoptic neurons under physiological and osmotic stress conditions. Mol Cell Neurosci 2008, 37:622-633.
45. Davies JE, Sarkar S, Rubinsztein DC: Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. Hum Mol Genet 2008, 17:1097-1108. This paper on the most studied transgenic mice model of OPMD provides strong evidence that the wild-type PABPN1 can rescue the phenotype to some extent. It demonstrates that knocking down the expression of PABPN1 leads to greater susceptibility to proapoptotic stresses, suggesting that wild-type PABPN1 appears to have an antiapoptotic function that may be mediated in part by the X-linked inhibitor of apoptosis protein. (Pubitemid 351505885)
46. Klein AF, Ebihara M, Alexander C, et al.: PA BPN1 polya lanine tract deletion and long expansions modify its aggregation pattern and expression. Exp Cell Res 2008, 314:1652-1666. This paper shows that the polyalanine domain of PABPN1 is not essential for its aggregation but for its proper transport across the nuclear membrane. It also shows that larger-size expansion in the 25-40Ala range leads to more toxicity without a greater formation of aggregates; in fact, with the larger 40Ala construct no clear aggregation was produced despite the higher toxicity.
47. Pellerin HG, Nicole PC, Trepanier CA, et al.: Postoperative complications in patients with oculopharyngeal muscular dystrophy: a retrospective study. Can J Anaesth 2007, 54:361-365. (Pubitemid 46902015)
48. Mathieu J, Lapointe G, Brassard A, et al.: A pilot study on upper esophageal sphincter dilatation for the treatment of dysphagia in patients with oculopharyngeal muscular dystrophy. Neuromuscul Disord 1997, 7:S100-S104.
49. Hill ME, Creed GA, McMullan TF, et al.: Oculopharyngeal muscular dystrophy: phenotypic and genotypic studies in a UK population. Brain 2001, 124(Pt 3):522-526. (Pubitemid 32221319)